<P> The genetic material in retroviruses is in the form of RNA molecules, while the genetic material of their hosts is in the form of DNA . When a retrovirus infects a host cell, it will introduce its RNA together with some enzymes, namely reverse transcriptase and integrase, into the cell . This RNA molecule from the retrovirus must produce a DNA copy from its RNA molecule before it can be integrated into the genetic material of the host cell . The process of producing a DNA copy from an RNA molecule is termed reverse transcription . It is carried out by one of the enzymes carried in the virus, called reverse transcriptase . After this DNA copy is produced and is free in the nucleus of the host cell, it must be incorporated into the genome of the host cell . That is, it must be inserted into the large DNA molecules in the cell (the chromosomes). This process is done by another enzyme carried in the virus called integrase . </P> <P> Now that the genetic material of the virus has been inserted, it can be said that the host cell has been modified to contain new genes . If this host cell divides later, its descendants will all contain the new genes . Sometimes the genes of the retrovirus do not express their information immediately . </P> <P> One of the problems of gene therapy using retroviruses is that the integrase enzyme can insert the genetic material of the virus into any arbitrary position in the genome of the host; it randomly inserts the genetic material into a chromosome . If genetic material happens to be inserted in the middle of one of the original genes of the host cell, this gene will be disrupted (insertional mutagenesis). If the gene happens to be one regulating cell division, uncontrolled cell division (i.e., cancer) can occur . This problem has recently begun to be addressed by utilizing zinc finger nucleases or by including certain sequences such as the beta - globin locus control region to direct the site of integration to specific chromosomal sites . </P> <P> Gene therapy trials using retroviral vectors to treat X-linked severe combined immunodeficiency (X-SCID) represent the most successful application of gene therapy to date . More than twenty patients have been treated in France and Britain, with a high rate of immune system reconstitution observed . Similar trials were restricted or halted in the USA when leukemia was reported in patients treated in the French X-SCID gene therapy trial . To date, four children in the French trial and one in the British trial have developed leukemia as a result of insertional mutagenesis by the retroviral vector . All but one of these children responded well to conventional anti-leukemia treatment . Gene therapy trials to treat SCID due to deficiency of the Adenosine Deaminase (ADA) enzyme (one form of SCID) continue with relative success in the USA, Britain, Ireland, Italy and Japan . </P>

What is one problem associated with using retroviruses as human gene therapy vectors